Beryllium Discovery
Specialized contract research for collaborative drug discovery.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
Related Content
Beryllium Discovery is a specialized contract research organization (CRO) that provides drug discovery services to the pharmaceutical and biotechnology industries. Founded in 1999, with some sources indicating a 2009 founding by Johan Pontin, the company partners with pharmaceutical, biotechnology, and academic institutions. Beryllium's business model is centered on providing research services and engaging in collaborative projects based on its drug discovery platform.
The company's service offerings include protein engineering, expression, and purification, as well as functional biology and protein structure determination designed to identify therapeutic drugs. Beryllium utilizes a biology-first, target-centric approach, leveraging its expertise to help clients navigate the challenges of early-stage drug discovery. The company's clients range from large pharmaceutical corporations to innovative biotech firms. In June 2017, Beryllium Discovery was acquired by UCB, a global biopharmaceutical company with which it had a long-standing partnership, including a previous minority stake investment.
Keywords: contract research organization, CRO, drug discovery, lead discovery, protein engineering, functional biology, protein structure, biopharmaceutical, biotechnology, pharmaceutical partners, collaborative research, therapeutic drugs, target-centric approach, gene-to-function, X-ray crystallography, protein purification